Department of Gastroenterology, National Hospital Organization, Shinshu Ueda Medical Center, Ueda, Japan.
Department of Laboratory Medicine, Shinshu University School of Medicine, Matsumoto, Japan.
Ann Diagn Pathol. 2021 Jun;52:151739. doi: 10.1016/j.anndiagpath.2021.151739. Epub 2021 Mar 31.
We investigated the expression of LGR5, the most robust and reliable known cancer stem cell (CSC) marker of colorectal cancer, and PD-L1 in tumor budding (TB), as well as clinicopathological features. Tissue microarrays (TMAs) were generated from TB samples from 32 stage II/III colorectal adenocarcinoma patients, and LGR5 expression in TMAs was evaluated by RNAscope, an extremely sensitive RNA in situ hybridization technique. LGR5 expression was significantly lower in the PD-L1-positive group than in the PD-L1-negative group (P = 0.0256). In the PD-L1-positive group, the tumor-infiltrating lymphocytes (TILs) score tended to be higher while the TNM stage was lower compared with the PD-L1 negative group (P = 0.0822 and P = 0.0765, respectively). There was no significant difference in Overall Survival between the PD-L1-positive and PD-L1-negative groups (log-rank test, P = 0.8218). This study showed that PD-L1-positive patients are a unique population with low LGR5 expression, and that LGR5-positive cells may be a promising therapeutic target in PD-L1-negative patients.
我们研究了 LGR5（结直肠癌最具活力和可靠性的已知癌症干细胞标志物）和 PD-L1 在肿瘤芽生（TB）中的表达，以及临床病理特征。从 32 名 II/III 期结直肠腺癌患者的 TB 样本中生成组织微阵列（TMA），并通过 RNAscope（一种极其敏感的 RNA 原位杂交技术）评估 TMA 中的 LGR5 表达。PD-L1 阳性组的 LGR5 表达明显低于 PD-L1 阴性组（P=0.0256）。与 PD-L1 阴性组相比，PD-L1 阳性组的肿瘤浸润淋巴细胞（TILs）评分较高，而 TNM 分期较低（分别为 P=0.0822 和 P=0.0765）。PD-L1 阳性组和 PD-L1 阴性组之间的总生存率无显著差异（对数秩检验，P=0.8218）。这项研究表明，PD-L1 阳性患者是一个具有低 LGR5 表达的独特人群，而 LGR5 阳性细胞可能是 PD-L1 阴性患者的一个有前途的治疗靶点。
